FibroBiologics Files 2024 First Quarter Report

Rhea-AI Summary

FibroBiologics has filed its 2024 Q1 report, ending March 31, 2024. The clinical-stage biotech firm, with over 150 patents, focuses on developing therapeutics for chronic diseases using fibroblasts. The 10-Q form is accessible on their website.

Positive

• Filed Q1 report on time, indicating regulatory compliance.
• 150+ patents, showcasing strong intellectual property.
• Focus on chronic diseases, a lucrative market.

Negative

• Lack of detailed financial data in the press release.
• Unclear clinical trial progress or results.
• Potential investor uncertainty without detailed financial metrics.

HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, with the U.S. Securities and Exchange Commission.

The filing can be viewed through a link on FibroBiologics’ website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports.

About FibroBiologics 
Based in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

What is FibroBiologics' stock symbol?

FibroBiologics' stock symbol is FBLG.

When did FibroBiologics file its Q1 2024 report?

FibroBiologics filed its Q1 2024 report on May 14, 2024.

What does FibroBiologics focus on?

FibroBiologics focuses on developing therapeutics for chronic diseases using fibroblasts.

Where can I view FibroBiologics’ Q1 2024 report?

You can view the Q1 2024 report on FibroBiologics' investor relations website.

How many patents does FibroBiologics have?

FibroBiologics has over 150 patents issued and pending.